Common questions about Intal (BRONCHODILATOR) (FAQ)
Q: What kind of environmental triggers can Intal help prevent reactions to?
Official documents indicate that this medication is used to reduce the likelihood of bronchospasm caused by a variety of triggers. These include specific physical causes described in studies, such as exercise and cold dry air. It is also noted to help prevent reactions from exposure to sulfur dioxide, certain chemicals, environmental pollutants, and common allergens like animal dander.
Q: What are the signs of a serious or severe reaction to Intal that require attention?
Serious reactions highlighted in regulatory documents include laryngeal edema (swelling of the voice box) and angioedema (swelling). The labeling describes immediate signs of a severe allergic reaction, which include hives, difficulty breathing or swallowing, and swelling of the face, lips, tongue, or throat.
Q: What is the difference between the Intal metered-dose inhaler and the nebulizer solution?
Intal may be provided in two forms: a nebulizer solution and a metered-dose inhaler (MDI) aerosol. The nebulizer solution is typically a clear, colorless, aqueous solution that requires use with a machine. The MDI is an aerosol product. Both are considered to have the same therapeutic purpose, though they may have different age restrictions for use.
Q: Are there different forms of Intal (e.g., capsule, liquid) and what are their intended uses?
Yes, the active ingredient cromolyn sodium is used in different forms for different purposes. The oral capsule or solution form, known by the brand Gastrocrom, is prescribed to treat the symptoms of mastocytosis. The intended use of the capsule powder is oral administration, mixed with water and taken by mouth.
Q: Why do some sources refer to Intal as a 'controller' medicine?
The term 'controller' is often used to describe medications taken regularly to prevent symptoms and reduce airway sensitivity. Intal's function is prophylactic (preventive) in nature, acting as a mast cell stabilizer to prevent the release of inflammatory mediators. This long-term, protective action fits the general description of a controller medication.
Q: Is it important to keep using Intal even when asthma symptoms are stable?
The medication is intended for continuous, preventive use, not for immediate relief. Regulatory documents note that asthma symptoms may recur if the medication is reduced below the recommended dosage or discontinued. This indicates that consistent administration is noted as key to maintaining the protective effect.
Q: Does Intal address inflammation in the airways?
While the medication is distinct from corticosteroids, its active ingredient, cromolyn sodium, is chemically designated as an inhaled anti-inflammatory agent. It works by preventing the release of various chemicals that trigger airway irritation.
Q: Does Intal contain corticosteroids or is it a steroid-free option?
Intal’s active ingredient is cromolyn sodium, a mast cell stabilizer. Official labeling describes this substance as an anti-inflammatory agent, but states that it has no intrinsic bronchodilator or antihistaminic activity. Based on its chemical structure and pharmacological action, the drug is not classified as a corticosteroid.
Q: Are there any reported long-term safety concerns associated with the use of Intal for many years?
Regulatory experience with the drug indicates that long-term use has not been associated with significant adverse effects. Non-clinical studies in animals also showed no evidence of carcinogenesis (cancer risk).
Q: Is it normal to notice an unusual or unpleasant taste in the mouth when using Intal?
According to official drug information, a potential side effect that may be reported with the use of inhaled cromolyn sodium is a bad or unpleasant taste in the mouth. This is generally a mild, non-serious reaction.
Q: Does Intal interact with common over-the-counter pain medications?
Due to minimal systemic absorption into the bloodstream from inhalation, the potential for significant drug-drug interactions with other medicinal products is generally considered low. Regulatory documents recommend that a healthcare provider be informed of all prescription and over-the-counter medicines being used.
Q: Can Intal be used safely with other maintenance asthma medications?
Asthma management frequently requires a combination of drugs to control symptoms. Regulatory documents do not cite major contraindications with other drug classes. Official guidance emphasizes using all medications exactly as directed by a healthcare provider.
Q: Is Intal commonly prescribed for conditions other than bronchial asthma?
Yes. While the inhaled form is for asthma prevention, the oral formulation of cromolyn sodium is also indicated for the treatment of mastocytosis. This condition involves an excessive accumulation of mast cells in the body.
Q: Why is it described that Intal must be used at regular intervals throughout the day?
Official patient information states that the medication is taken at regular intervals to keep a steady amount of the drug in your body at all times. This consistent schedule is intended to keep a steady amount of the drug in the body, which helps to maintain the continuous prophylactic effect required for prevention.
Q: Does the Intal inhaler contain propellants or other inactive ingredients that patients should be aware of?
Specific inactive ingredients vary by formulation. The inhalation solution vials are manufactured from low-density polyethylene (LDPE) resin and contain Purified Water. The complete list of ingredients for a specific product type is contained within the official product labeling.
Q: Are there studies on whether Intal can help reduce the required dose of inhaled steroids?
A satisfactory response to therapy may be indicated by a decreased requirement for other drugs used in asthma treatment. This includes a decreased requirement for corticosteroids.
Q: How is Intal generally classified in major international treatment guidelines?
Intal is recognized for offering a new approach to asthma management through mast cell stabilization, distinct from bronchodilators and steroids. It is considered an important adjunct (supplemental) option for long-term prophylactic therapy, often used as an alternative non-corticosteroid choice.
Q: What is the meaning of the term 'bronchial asthma' in the context of Intal's indication?
Intal is indicated for the prevention of bronchial asthma attacks. This typically refers to the chronic respiratory condition characterized by recurrent symptoms such as shortness of breath, wheezing, and coughing.
Q: What kind of specific safety monitoring is recommended for patients using Intal long-term?
While there is no standard long-term monitoring protocol specified for all users, specific consideration is advised for patients with impaired renal or hepatic function, as this may necessitate closer monitoring of kidney or liver function.
Q: Is Intal known to cause drowsiness or dizziness?
The official adverse reaction list for the active ingredient, cromolyn sodium, does include dizziness as a potential side effect, though it is reported very rarely (in less than 1 in 10,000 patients). Drowsiness is generally not listed among the recognized common or uncommon side effects.
Q: Can Intal be used if someone is allergic to other common medications?
Regulatory documents state that the medication is contraindicated only in patients who have shown hypersensitivity to cromolyn sodium or any other component in the preparation. Other medication allergies are not listed as a contraindication.
Q: Are there any interactions noted between Intal and tobacco use?
Official patient information advises individuals with asthma to not smoke. The patient information notes that asthmatic patients are advised to avoid staying in the same room with people who smoke, as tobacco smoke can act as an asthma trigger.
Q: What evidence exists regarding Intal's effectiveness for non-allergic (intrinsic) asthma?
Studies on the medication's effectiveness suggest that younger patients with extrinsic (allergic) asthma may respond more favorably than older patients who have intrinsic (non-allergic) asthma. The prophylactic effect may vary based on the underlying cause of the asthma.
Q: How is the use of Intal generally managed in older (geriatric) patient populations?
Official documents state that caution and specific consideration are required for elderly patients. This often includes renal function monitoring and a gradual titration to a lower starting dose due to potential changes in drug clearance with age.
_EN.png)
